ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Albany Molecular Lands NIH Contract

by Rick Mullin
August 29, 2011 | APPEARED IN VOLUME 89, ISSUE 35

Albany Molecular Research Inc. has won a five-year contract from NIH and the National Institute of Neurological Disorders & Stroke to provide chemistry and other drug discovery technology in support of NINDS’s Medicinal Chemistry for Neurotherapeutics Program. AMRI will receive $10 million in funding for the first phase of the project, with the objective of delivering at least one Phase I clinical-trial candidate. The firm stands to receive as much as $43 million for the full contract. AMRI has collaborated with NINDS since 2005 on treating spinal muscular atrophy.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment